Erschienen in:
19.06.2023 | ASO Perspectives
Adding Stereotactic Radiation to the Multidisciplinary Armamentarium for Localized Renal Cell Carcinoma: Ready for Primetime?
An Editorial Regarding a Recent 5-Year Efficacy and Safety Report of a Multicenter Cohort of Primary RCC Patients Treated with SABR
verfasst von:
Elizabeth L. Koehne, MD, Sarah P. Psutka, MD, MSc
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 12/2023
Einloggen, um Zugang zu erhalten
Excerpt
Recent publications have highlighted the potential utility of stereotactic ablative body radiotherapy (SABR) in the management of localized
1,2 and metastatic
2,3 renal cell carcinoma, specifically for patients whose competing comorbidities, frailty, and/or baseline renal insufficiency preclude definitive conventional treatment.
The Lancet Oncology recently published the report of Siva et al.
4 detailing 5-year efficacy and safety results from a retrospective, multicenter review of 12 institutions across five countries performing SABR as primary treatment for nonmetastatic renal cell carcinoma (RCC). Most of the patients (83 %, 157/190) in the cohort underwent biopsy before treatment, and 23 (12 %) had a non-clear cell histology. With a median follow-up period of 5 years, this is the most mature follow-up evaluation reported for SABR as definitive therapy used to treat localized RCC to date. The primary end point was investigator-assessed local failure as per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. The secondary end points were treatment-related toxicity, patterns of failure, and change in renal function. …
